CoChat
Sign Up
Cited by 291Systemic Lupus Erythematosus ResearchBlood Coagulation and Thrombosis MechanismsVenous Thromboembolism Diagnosis and Management

The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.

The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus

Jung, Hyejung, Bobba, Raja, Su, Jiandong, Shariati‐Sarabi, Zhaleh, Gladman, Dafna D., Urowitz, Murray, Lou, Wendy, Fortin, Paul R.·2010·Arthritis & Rheumatism
DOI 10.1002/art.27289
Open this paper in CoChat — free account

Abstract

Objective: The antimalarial medication hydroxychloroquine has been proposed as a thromboprotective agent in systemic lupus erythematosus (SLE), but studies thus far have been limited by the possibility of confounding by indication. This study was conducted to assess whether exposure to antimalarial drugs is associated with a decrease in thrombovascular events (TEs) in patients with SLE. Methods: The study was designed as a nested case–control study embedded in an inception cohort of patients with SLE, which allowed adjustments for possible confounding by calendar year, duration of disease, duration of observation, and severity of lupus. After controlling for the possible confounding variables in conditional logistic regression models, the use of antimalarial drugs was assessed for its effects on the development of TEs in lupus patients. Results: Fifty‐four cases of TE were identified, and these were matched with 108 control subjects (lupus patients without TEs). Univariate analyses identified older age (odds ratio [OR] 1.04, 95% confidence interval [95%CI] 1.01–1.07) or being older than age 50 years (OR 3.5, 95% CI 1.4–8.6) and ever having hypertension (OR 2.5, 95% CI 1.0–5.8) as being associated with an increased risk of TEs, whereas use of antimalarial drugs (OR 0.31, 95% CI 0.13–0.71) was associated with a decreased risk of TEs. Separate analyses were done for arterial and venous TEs, which yielded similar results. In multivariate analyses, use of antimalarial drugs (OR 0.32, 95% CI 0.14–0.74) and older age (OR 1.04, 95% CI 1.01–1.07) were the only 2 variables that remained significant. Conclusion: The results from this nested case–control study demonstrate that, after accounting for the effects of disease severity, disease duration, and calendar year, antimalarial drugs were found to be thromboprotective, being associated with a 68% reduction in the risk of all TEs, with a range of risk reduction of at least 26% up to as high as 86%.

Overview

Integrity signals

Registry

Crossref · 10.1002/art.27289

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 33 references

1 of the 33 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Items 201–291 of 291

Related

See all

Metadata

Authors
Jung, H., Bobba, R., Su, J., Shariati‐Sarabi, Z., Gladman, D. D., Urowitz, M., Lou, W., & Fortin, P. R.
Affiliations
  • University of Toronto (CA)
  • McMaster University (CA)
  • Mashhad University of Medical Sciences (IR)
ORCID
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2010-02-25
Volume
62
Issue
3
Pages
863-868
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
DOI
10.1002/art.27289
OpenAlex
W2024228574
Cited by
291
References
33
Citations by year
2026: 7 · 2025: 11 · 2024: 17 · 2023: 9 · 2022: 18 · 2021: 28 · 2020: 20 · 2019: 15 · 2018: 24 · 2017: 22 · 2016: 23 · 2015: 16 · 2014: 23 · 2013: 16 · 2012: 22
FWCI
12.71
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Arthritis & Rheumatism (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Toronto
  • Canadian Institutes of Health Research (49509_1, 64336_1)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords
hydroxychloroquine, antimalarial drugs, systemic lupus erythematosus, venous thromboembolism, arterial thromboembolism, hypertension, age as risk factor, confounding by indication
MeSH terms
Adult, Antimalarials, Female, Humans, Hydroxychloroquine, Lupus Erythematosus, Systemic, Male, Middle Aged, Thrombosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review